Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055
when combined with erlotinib and bevacizumab in patients with previously treated advanced
NSCLC.